Clinical Trial Update: A Phase 3, Multicenter Study To Evaluate The Efficacy And Safety Of MOD-4023 In Adults With Growth Hormone Deficiency [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating MOD-4023 in adults with growth hormone deficiency was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Hormone Deficiency

Drugs mentioned

• MOD-4023 (long-acting growth hormone)

Snippet

Sponsor: OPKO Health, Inc. | Conditions: Adult Growth Hormone Deficiency | Phase 3 | Status: TERMINATED | Results posted: 2022-08-12